Ignite Creation Date:
2024-05-06 @ 1:27 PM
Last Modification Date:
2024-10-26 @ 1:14 PM
Study NCT ID:
NCT04023721
Status:
TERMINATED
Last Update Posted:
2020-07-22
First Post:
2019-06-21
Brief Title:
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor
Sponsor:
F-star Therapeutics Inc
Organization:
F-star Therapeutics Inc
Study Overview
Official Title:
A Phase 2 Exploratory Study Evaluating the Safety and Antiviral Efficacy of Inarigivir Soproxil in Non-cirrhotic Hepatitis B e Antigen-negative Subjects Infected With Chronic Hepatitis B Virus and Receiving or Stopping Treatment With a NucleosideNucleotide Inhibitor
Status:
TERMINATED
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Safety
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An open-label Phase 2 exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic hepatitis B e antigen HBeAg-negative subjects with chronic HBV infection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None